Recurrent or Metastatic Breast Cancer Clinical Trial
Official title:
A Multi-national,Multi-center, Open-label, Phase 2 Clinical Trial to Evaluate the Efficacy, Safety and Pharmacokinetics of DHP107 (Liporaxel®,Oral Paclitaxel) Compared to IV Paclitaxel in Patients With Recurrent or Metastatic Breast Cancer(OPERA)
The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of DHP107 (Oral Paclitaxel, Korea brand name: Liporaxel®) compared to IV Paclitaxel in patients with Recurrent or Metastatic Breast Cancer.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03947736 -
Dynamic Monitoring of HER2 and ctDNA Specific Mutations in Patients With Recurrent or Metastatic Breast Cancer by Digital PCR
|
||
Completed |
NCT03109249 -
Pharmacokinetic Study of SPARC1613 and reference1613 in Subjects With Locally Recurrent or Metastatic Breast Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03315364 -
Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy
|
Phase 2/Phase 3 |